Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Tolerability and Efficacy of Intravenous Infusion of Autologous MSC_Apceth for the Treatment of Critical Limb Ischemia

This study has been terminated.
(The primary outcome of this open clinical trial "Safety & Tolerability of MSC-Apceth" was achieved with the minimum number of patients needed.)
Sponsor:
Information provided by (Responsible Party):
Apceth GmbH & Co. KG
ClinicalTrials.gov Identifier:
NCT01351610
First received: May 10, 2011
Last updated: November 5, 2014
Last verified: November 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: December 2014
  Primary Completion Date: October 2014 (Final data collection date for primary outcome measure)